-
C34 TLR4 Inhibitor Workflow for Inflammation Research
2026-08-17
C34 provides a selective way to dissect TLR4-driven inflammation in macrophage, enterocyte, and exploratory microglial assays. This workflow connects concentration-controlled inhibition with the TLR4/NF-κB/NLRP3 findings reported for Taxus chinensis fruit extract, while emphasizing controls, assay fit, and troubleshooting.
-
Aprotinin Workflows for Protease Research
2026-08-16
Aprotinin enables controlled, reversible inhibition of trypsin, plasmin, and kallikrein in biochemical, inflammation, and fibrinolysis studies. This guide pairs practical BPTI assay design with lessons from an economical GRO-seq workflow, while clearly separating validated applications from exploratory cross-domain ideas.
-
Carrier-Platin and Rapid ROS-Driven Cancer Cell Death
2026-08-15
Liu et al. developed carrier-platin, a platinum-based nanotherapeutic that confines ultrasmall platinum nanoparticles within a poly(amino acid) carrier to generate a rapid intracellular ROS burst. The resulting cancer-cell death occurs within minutes, is independent of DNA damage, and differs from canonical apoptosis and ferroptosis, while showing activity in multidrug-resistant tumor models with limited systemic toxicity.
-
EZ Cap™ Human PTEN mRNA: Assay Design
2026-08-14
EZ Cap™ Human PTEN mRNA (ψUTP) enables controlled PTEN restoration studies with Cap 1, pseudouridine, and a poly(A) tail. This article presents a causal assay-design framework linking mRNA engineering, delivery, PI3K/Akt signaling, and cancer research outcomes.
-
FK866 (APO866): NAMPT Inhibition in Cancer
2026-08-14
FK866, also called APO866, is a potent non-competitive NAMPT inhibitor that lowers intracellular NAD and ATP. It is a research tool for hematologic cancer research, especially acute myeloid leukemia (AML) treatment research, but its activity is model-dependent and does not establish clinical efficacy.
-
ASCH Proteins and N4-Acetylcytidine Processing
2026-08-13
Meng et al. define how the ASCH-domain enzyme EcYqfB converts free N4-acetylcytidine into cytidine while showing that it is not responsible for removing ac4C from RNA. Comparative structures of EcYqfB, mouse EOLA1, and the human TRIP4-ASCH domain clarify substrate-pocket differences and support more precise designs for RNA modification and nucleotide-processing studies.
-
Protease Inhibitor Cocktail for Lipid Droplet Assays
2026-08-13
Preserve DFCP1–ATGL complexes, lipid-droplet proteins, and signaling readouts during starvation experiments with a water-soluble, EDTA-containing inhibitor mixture. This workflow-focused guide explains when to use the cocktail, how to protect samples without compromising downstream assays, and how to troubleshoot metal-sensitive applications.
-
G-Quadruplexes, TDP-43 Condensation, and Toxicity
2026-08-12
Oldani et al. show that G-quadruplexes directly influence TDP-43 aggregation, localization, and toxicity across biochemical and cellular models. The study supports a structure-focused view of RNA–protein misfolding and suggests that manipulating G-quadruplex populations could modulate disease-relevant TDP-43 condensates, while remaining preclinical.
-
Sumatriptan as an Anti-Inflammatory Agent: Review
2026-08-12
This systematic review reframes sumatriptan, traditionally used for migraine and cluster headache, as a potential modulator of inflammatory signaling. By synthesizing 66 studies, it connects 5-HT1B/1D receptor activity with cytokine regulation, nitric oxide signaling, CGRP release, and protection in several experimental injury models.
-
Toremifene Citrate: Reliable Assay Workflows
2026-08-11
A scenario-driven guide to using Toremifene Citrate (SKU B1513) in estrogen receptor signaling, breast cancer research, and cell-based viability workflows. It connects receptor-level potency, solvent handling, concentration design, data interpretation, and vendor-selection criteria to improve experimental consistency.
-
Protease Inhibitor Cocktail for OXPHOS Assays
2026-08-11
Protect intact LRPPRC and OXPHOS-related proteins during cell and tissue extraction with an EDTA-free, broad-spectrum formulation. This workflow connects dependable sample preparation with mechanistic studies of LRPPRC inhibition and dasatinib synergy, while addressing co-IP, Western blot, kinase-assay, and tissue-extract challenges.
-
Topotecan HCl: From DNA Lesions to Translation
2026-08-10
Topotecan HCl offers translational researchers a mechanistically defined topoisomerase 1 inhibitor for linking replication-associated DNA damage with measurable tumor-cell outcomes. This thought-leadership perspective connects target biology, response kinetics, model selection, schedule design, comparative activity, and preclinical safety interpretation.
-
Metformin HCl and AMPK in Vocal Fold Fibrosis
2026-08-09
A translational analysis of how Metformin Hydrochloride engages AMPK-linked antifibrotic biology, what the vocal fold fibrosis evidence supports, and how researchers can design more decision-ready experiments.
-
Nigericin: pH Modulation for Translational Assays
2026-08-08
Nigericin gives researchers a practical way to perturb potassium–proton exchange, intracellular pH, and mitochondrial ion gradients in controlled cell-based assays. This guide translates that mechanism into oncology, mitochondrial, and carefully bounded antibiotic-potentiation workflows while emphasizing controls, solvent handling, and interpretation limits.
-
Nanoparticle mRNA Delivery to Reverse Trastuzumab Resistance
2026-08-07
Dong and colleagues developed a tumor-microenvironment-responsive nanoparticle system for intravenous delivery of PTEN mRNA to trastuzumab-resistant HER2-positive breast cancer models. The approach restored PTEN expression, inhibited persistently active PI3K/Akt signaling, and improved the ability of trastuzumab to suppress tumor growth, while also illustrating the formulation and delivery requirements for systemic in vitro transcribed mRNA therapy.